Selepressin a novel selective vasopressin V1A agonist is an effective substitute for norepinephrine in a phase IIa randomized placebo-controlled trial in septic shock patients

摘要

BackgroundVasopressin is widely used for vasopressor support in septic shock patients, but experimental evidence suggests that selective V1A agonists are superior. The initial pharmacodynamic effects, pharmacokinetics, and safety of selepressin, a novel V1A-selective vasopressin analogue, was examined in a phase IIa trial in septic shock patients.